Novartis AG NVS

NVS Company Overview

Novartis AG is a Swiss multinational pharmaceutical company focused on innovative medicines, operating primarily in the global healthcare and biopharmaceutical industries. The company develops, manufactures, and commercializes prescription medicines across multiple therapeutic areas, including oncology, cardiovascular, immunology, neuroscience, and renal diseases. Following the spin-off of its generics and biosimilars business, Sandoz, in 2023, Novartis has increasingly positioned itself as a “pure-play” innovative medicines company centered on patented therapies and advanced drug platforms. Its principal revenue drivers include branded medicines such as Entresto, Cosentyx, Kesimpta, Kisqali, Pluvicto, and Leqvio, with substantial contributions from oncology and cardiovascular products.

Novartis traces its origins to the 1996 merger of Swiss companies Ciba-Geigy and Sandoz. Over time, the company expanded through acquisitions, internal research, and strategic partnerships while streamlining its portfolio by divesting non-core businesses. Major historical transactions include the acquisition of AveXis in gene therapy and the restructuring of ownership stakes with companies such as Roche and GSK. The company emphasizes science-driven innovation, advanced therapeutics, and global commercialization capabilities, supported by significant research and development investment and a broad international footprint.